Amylyx Pharmaceuticals

Quarterly Financials

Values in thousands2025-09-302025-06-302025-03-312024-12-31
Revenue
$0
$0
$0
$-665
Gross Profit
-19,855
-141
0
-665
EBITDA
-34,266
-41,302
-37,647
-40,494
EBIT
-34,386
-41,443
-37,803
-40,654
Net Income
-34,386
-41,443
-35,907
-37,546
Net Change In Cash
0
0
0
-665
Free Cash Flow
-30,392
-25,265
-39,835
-59,028
Cash
225,178
58,085
59,764
77,391
Basic Shares
93,332
89,138
85,697
68,593

Annual Financials

Values in thousands2024-12-312023-12-312022-12-312021-12-31
Revenue
$87,371
$380,786
$22,230
$285
Gross Profit
45,215
355,345
19,237
285
EBITDA
-290,976
39,890
-200,854
-82,636
EBIT
-291,880
38,802
-201,341
-82,688
Net Income
-301,743
49,271
-198,375
-87,879
Net Change In Cash
87,371
380,786
22,230
285
Cost of Revenue
12,930
Free Cash Flow
-167,804
10,678
-182,397
-75,152
Cash
77,391
170,201
62,526
50,191
Basic Shares
68,142
69,991
66,512
57,864

Earnings Calls

QuarterEPS
2025-09-30
-$0.37
2025-06-30
-$0.46
2025-03-31
-$0.42
2024-12-31
-$0.55